Scarica l'app Stockscreener
144.48
2.48%
3.50
Dopo l'orario di chiusura:
144.49
0.01
+0.01%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$140.98
Aprire:
$142.39
Volume 24 ore:
1.82M
Relative Volume:
0.77
Capitalizzazione di mercato:
$31.19B
Reddito:
$606.42M
Utile/perdita netta:
$-1.28B
Rapporto P/E:
-22.56
EPS:
-6.403
Flusso di cassa netto:
$-997.58M
1 W Prestazione:
-1.54%
1M Prestazione:
+6.24%
6M Prestazione:
-9.93%
1 anno Prestazione:
+102.81%
Intervallo 1D:
$141.43
$145.32
Intervallo di 1 settimana:
$139.59
$146.18
Portata 52W:
$63.81
$212.75
Insmed Inc Stock (INSM) Company Profile
Nome
Insmed Inc
Settore
Industria
Telefono
908-977-9900
Indirizzo
700 US HIGHWAY 202/206, BRIDGEWATER, NJ
Compare INSM vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
INSM
Insmed Inc
|
144.48 | 30.43B | 606.42M | -1.28B | -997.58M | -6.403 |
VRTX
Vertex Pharmaceuticals Inc
|
437.67 | 111.05B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
746.58 | 79.01B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
793.22 | 50.08B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
310.58 | 41.15B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
312.41 | 34.67B | 5.36B | 287.73M | 924.18M | 2.5229 |
Insmed Inc Stock (INSM) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-10 | Iniziato | Raymond James | Outperform |
| 2026-03-30 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2026-03-16 | Ripresa | Jefferies | Buy |
| 2026-01-28 | Iniziato | Barclays | Overweight |
| 2026-01-23 | Iniziato | Roth Capital | Buy |
| 2025-12-19 | Ripresa | Truist | Buy |
| 2025-12-04 | Iniziato | Rothschild & Co Redburn | Buy |
| 2025-10-28 | Ripresa | Cantor Fitzgerald | Overweight |
| 2025-10-20 | Iniziato | Wells Fargo | Overweight |
| 2025-08-20 | Iniziato | William Blair | Outperform |
| 2025-08-13 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2025-05-13 | Iniziato | Jefferies | Buy |
| 2025-02-25 | Iniziato | RBC Capital Mkts | Outperform |
| 2024-04-23 | Iniziato | Truist | Buy |
| 2024-02-15 | Iniziato | Wolfe Research | Outperform |
| 2023-12-08 | Iniziato | Wells Fargo | Overweight |
| 2023-11-20 | Ripresa | JP Morgan | Overweight |
| 2023-07-26 | Iniziato | Guggenheim | Buy |
| 2022-12-09 | Iniziato | Mizuho | Buy |
| 2022-12-07 | Iniziato | Barclays | Overweight |
| 2022-11-18 | Iniziato | BofA Securities | Buy |
| 2022-04-27 | Iniziato | Goldman | Buy |
| 2021-12-06 | Iniziato | JP Morgan | Overweight |
| 2021-10-19 | Ripresa | Monness Crespi & Hardt | Buy |
| 2021-10-19 | Ripresa | Morgan Stanley | Overweight |
| 2021-10-08 | Iniziato | Cantor Fitzgerald | Overweight |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2020-12-17 | Iniziato | Berenberg | Buy |
| 2020-10-12 | Ripresa | Stifel | Buy |
| 2019-09-03 | Iniziato | Goldman | Buy |
| 2019-04-09 | Reiterato | H.C. Wainwright | Buy |
| 2019-02-15 | Aggiornamento | JMP Securities | Mkt Perform → Mkt Outperform |
| 2019-01-17 | Aggiornamento | Goldman | Neutral → Buy |
| 2019-01-02 | Iniziato | Canaccord Genuity | Buy |
| 2018-08-06 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2018-07-23 | Iniziato | Goldman | Neutral |
| 2018-04-23 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2018-03-21 | Iniziato | Morgan Stanley | Overweight |
| 2018-01-18 | Iniziato | Credit Suisse | Neutral |
| 2017-09-05 | Reiterato | Evercore ISI | Outperform |
| 2017-08-17 | Iniziato | Evercore ISI | Outperform |
| 2017-07-11 | Iniziato | Robert W. Baird | Outperform |
| 2016-03-15 | Iniziato | Stifel | Buy |
| 2015-11-09 | Downgrade | UBS | Buy → Neutral |
| 2015-10-06 | Reiterato | H.C. Wainwright | Buy |
| 2015-06-09 | Iniziato | Citigroup | Neutral |
| 2014-03-26 | Reiterato | HC Wainwright | Buy |
Mostra tutto
Insmed Inc Borsa (INSM) Ultime notizie
Insmed Inc stock (US4576693075): Is the rare disease pipeline strong enough to unlock new upside? - AD HOC NEWS
Insmed Incorporated (INSM) Stock Analysis: Potential 47% Upside With Strong Buy Ratings - DirectorsTalk Interviews
Insmed Stock Hits Day Low of $135.73 Amid Price Pressure - Markets Mojo
INSM Reiterates by Roth Capital -- Price Target Maintained at $2 - GuruFocus
Insmed chair and CEO William Lewis sells $1.54m in stock - Investing.com
Insider Selling: Insmed (NASDAQ:INSM) CEO Sells 10,699 Shares of Stock - MarketBeat
INSMED (INSM) CEO exercises options and sells 10,699 shares under 10b5-1 plan - Stock Titan
Roth Mkm Reaffirms "Buy" Rating for Insmed (NASDAQ:INSM) - MarketBeat
Roth MKM Maintains Insmed(INSM.US) With Buy Rating, Maintains Target Price $212 - Moomoo
William Lewis lists INSM share sales (NASDAQ: INSM) in Form 144 filing - Stock Titan
Guggenheim raises Insmed stock price target to $230 on Arikayce By Investing.com - Investing.com Canada
Guggenheim Maintains Insmed(INSM.US) With Buy Rating, Raises Target Price to $230 - Moomoo
Insmed, Inc. (NASDAQ:INSM) Short Interest Update - MarketBeat
Insmed (INSM) soars 5.5%: Is further upside left in the stock? - MSN
Insmed Inc stock (US4576693075): Is brensocatib approval the real test for rare disease growth? - AD HOC NEWS
Sumitomo Mitsui Trust Group Inc. Purchases Shares of 435,442 Insmed, Inc. $INSM - MarketBeat
INSM Maintained by RBC Capital -- Price Target Raised to $216 - GuruFocus
Insmed Sees Favorable Physician Feedback on Brinsupri, RBC Capital Markets Says - Moomoo
Oak Ridge Investments LLC Trims Position in Insmed, Inc. $INSM - MarketBeat
RBC Raises Price Target on Insmed to $216 From $212, Keeps Outperform Rating - marketscreener.com
RBC Capital Maintains Insmed(INSM.US) With Buy Rating, Raises Target Price to $216 - Moomoo
RBC Capital raises Insmed stock price target on Brinsupri outlook By Investing.com - Investing.com Canada
INSM Stock Price, Quote & Chart | INSMED INC (NASDAQ:INSM) - ChartMill
EBIT per share of Insmed Incorporated – BX:IM8N - TradingView — Track All Markets
Institution Moves: What are the future prospects of Insmed Incorporated2026 Market Mood & Risk Managed Investment Signals - baoquankhu1.vn
Insmed Incorporated (INSM): Billionaire Stan Druckenmiller trims stake - MSN
US Stocks Recap: Is URTY a cyclical or defensive stockGap Up & Verified Swing Trading Watchlist - baoquankhu1.vn
Risk Analysis: Is Insmed Incorporated stock a buy or sell2026 Trade Ideas & Reliable Momentum Entry Alerts - baoquankhu1.vn
Insmed (INSM): Top QQQ Stock to Buy Now - Yahoo Finance
Insmed Achieves $280 Million Trading Volume, Secures Leading Market Position Despite Positive Analyst Ratings and Clinical Challenges - Bitget
Here Are Friday’s Top Wall Street Analyst Research Calls: Autodesk, Delek US Holdings, Insmed, Nike, Nutanix, ServiceNow, Shake Shack, Southern Copper, Veeva Systems, and More - 24/7 Wall St.
What is HC Wainwright's Estimate for Insmed FY2027 Earnings? - MarketBeat
Is It Too Late To Consider Insmed (INSM) After A 146% One Year Surge? - Yahoo Finance
Insmed (INSM) poised for 2026 upside with potential $1.3B Arikayce sales boost, Roth/MKM initiates buy - MSN
Non Tuberculous Mycobacterial Infections Market: High-Growth Opportunities for Investors to 2034 – DelveInsight | Insmed, AN2 Therapeutics, Mannkind Corp., Spero Therapeutics, Savara Pharmaceuticals - Barchart.com
FRANKLIN GROWTH OPPORTUNITIES FUND's Insmed Inc(INSM) Holding History - GuruFocus
Insmed chair and CEO William Lewis sells $1.75 million in stock - Investing.com Nigeria
Insmed (INSM) Halts Brensocatib R&D After Trial Setback - GuruFocus
Insmed chair and CEO William Lewis sells $1.75 million in stock By Investing.com - Investing.com South Africa
Insmed Insider Sold Shares Worth $1,746,336, According to a Recent SEC Filing - Moomoo
Insmed (INSM) CEO sells shares, exercises options under 10b5-1 plan - Stock Titan
Trial Failure in the Skin Does Not Dent Insmed Drug’s Potential in the Lungs - MedCity News
Insmed Incorporated (INSM): Billionaire Stan Druckenmiller Trims Stake - Yahoo Finance
Interstitial Lung Disease Market to Witness Accelerated Growth at a CAGR of 8.7% During the Forecast Period (2026–2036) Due to the Launch of Emerging Therapies | DelveInsight - GlobeNewswire Inc.
Insmed Ends Brinsupri Development in Skin Disease Post Study Failure - Yahoo Finance
Insmed Drug Misses Primary Goal, Program Axed - Benzinga
Insmed freezes Brinsupri’s HS programme on Phase II failure - Yahoo Finance
Mizuho Trims Price Target on Insmed to $202 From $206, Keeps Outperform Rating - marketscreener.com
Insmed drops skin disorder candidate after mid-stage trial setback - Seeking Alpha
Insmed drops HS program for Brinsupri after Phase IIb miss - The Pharma Letter
Insmed stock falls after failed hidradenitis suppurativa trial By Investing.com - Investing.com South Africa
Insmed Inc Azioni (INSM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Insmed Inc Azioni (INSM) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Lewis William | Chair and CEO |
Apr 16 '26 |
Sale |
143.97 |
10,699 |
1,540,332 |
301,185 |
4.97%
0.03%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):